Mobile

A study in adult patients with Cardiovascular disease or at elevated risk of having Cardiovascular disease to evaluate whether the study drug (Dalcetrapib) is able to reduce the risk of experiencing a...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-001891-21

A study in adult patients with Cardiovascular disease or at elevated risk of having Cardiovascular disease to evaluate whether the study drug (Dalcetrapib) is able to reduce the risk of experiencing a cardiovascular event in the future such as a heart attack or a stroke by raising HDL cholesterol (also called “good”cholesterol)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in adult patients with stable coronary heart disease (CHD), CHD risk equivalents or at elevated risk for cardiovascular disease (CVD)

Critère d'inclusion

  • Patients with stable CHD, CHD risk equivalents (including PAD, cerebrovascular disease, and T2D), or at elevated risk for CV mortality and morbidity on the basis of multiple risk factors for CVD by raising HDL-C

Liens